 |
|
|
|
Ruze supply good service, thanks.
 |
—— Gaurav
- I'm Online Chat Now
Non Small Cell Lung Cancer Medications Lorlatinib(PF-06463922,1454846-35-5) White Powder
Product Details:
Payment & Shipping Terms:
|
Detailed Product Description
| Product Name: | PF-06463922 | CAS: | 1454846-35-5 |
|---|---|---|---|
| MF: | C21H19FN6O2 | MW: | 406.4129632 |
| EINECS: | 813-704-5 | Mol File: | 1454846-35-5.mol |
Weifang Ruze New Material Co.,LTD a China supplier of PF-06463922 (CAS No.:1454846-35-5 ),CAS1454846-35-5 offers for your requirements of RND, evaluation, pilots and commercial along with supportive technical package required for evaluation.
Lorlatinib(PF-06463922,1454846-35-5)
[Product Name]:PF-06463922
[CAS]:1454846-35-5
[MF]:C21H19FN6O2
[MW]:406.4129632
[EINECS]:813-704-5
[Assay]:98%min
[Appearance]:white Powder
[Stock]: less than 500g
[Customer Synthesis]: Avilable
Biological Activity of Lorlatinib(PF-06463922,1454846-35-5)
Description High affinity and selective ALK and ROS1 inhibitor (Ki values are <0.02, <0.07 and 0.7 nM for ROS1, wild-type ALK and ALK-L1196M, respectively). Exhibits >100-fold selectivity for ROS1 over a panel of 204 other kinases. Inhibits proliferation of BaF3 cells containing crizotinib-resistant ROS1 mutation in vitro. Inhibits tumor growth in relevant mouse models. Orally available and brain penetrant.
PF-06463922 Usage And Synthesis
| Uses | Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that promotes cell proliferation and blocks apoptosis. PF-06463922 is an ATP-competitive, selective inhibitor of ALK (Ki = < 0.07 nM) and c-Ros oncogene 1 (ROS1, Ki = 0.7 nM). It has strong activity against all known ALK and ROS1 mutants identified in patients, including the EML4-L1196M mutant of ALK (Ki = < 0.02 nM). PF-06463922 is orally available, displaying inhibition of ALK phosphorylation and antitumor efficacy in a xenograft model expressing EML4-L1196M ALK. It demonstrates efficient blood-brain barrier penetration, produces brain tumor regression in mice harboring EML4-ALK tumors, and increases overall survival.[Cayman Chemical] |
| Enzyme inhibitor | This potent, dual ALK/ROS1 inhibitor (FW = 406.41 g/mol; CAS 1454846- 35-5), also named (10R)-7-amino-12-fluoro-10,15,16,17-tetrahydro- 2,10,16-trimethyl-15-oxo-2H-4,8-methenopyrazolo[4,3- h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile, targets the protooncogene tyrosine-protein kinase ROS1 (Ki < 0.02 nM) as well as wild-type anaplastic lymphoma kinase ALKWT (Ki < 0.07 nM) and its Leu-to-Met mutant ALKL1196M (Ki of = 0.7 nM). PF-06463922 significantly inhibits cell proliferation and induces cell apoptosis in the HCC78 human NSCLC cells harboring SLC34A2-ROS1 fusions and the BaF3-CD74-ROS1 cells expressing human CD74-ROS1 |
Weifang Ruze New Material Co.,LTD supply free sample and datebase on PF-06463922 (CAS No.:1454846-35-5 ), if you want futher information about PF-06463922 (CAS No.:1454846-35-5 ), please feel free to contract us.
Contact Details
Weifang Ruze New Material Co., Ltd.
Contact Person: Ruze02
Other Products
-
Assay 99% Incb28060 Pharmaceutical Intermediates Cas 1029712-80-8 Yellow Powder
-
Customer synthesis Non Small Cell Lung Cancer Medications Dacomitinib (PF299804,1110813-31-4)99% assay
-
Off - White Solid 877399 52 5 Non Small Cell Lung Cancer Treatment Drugs Crizotinib
-
CAS 1421373-65-0 Non Small Cell Lung Cancer Medications AZD-9291 (Osimertinib)
-
Non Small Cell Lung Cancer Medications Crizotinib CAS New Medication For Lung Cancer
-
C29H39ClN7O2P Non Small Cell Lung Cancer Medications Brigatinib 99% Assay